Sanofi announced a $1.15 billion upfront acquisition of UK-based biotech Vicebio, gaining early-stage combination vaccine candidates targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). The purchase includes access to Vicebio’s proprietary Molecular Clamp technology, which stabilizes viral proteins to elicit stronger immune responses and streamline manufacturing. This move augments Sanofi’s existing vaccines portfolio, adding a non-mRNA platform to complement its current flu and RSV vaccines. The acquisition is anticipated to close by the end of 2025 without significant impact on Sanofi’s 2025 financial guidance.